Related Experiment Video
Updated: Jan 14, 2026

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
Recent advances in the study of Conbercept for diabetic macular edema
Zhe Liu1,2, Xin Zheng3, Hong Li4
1School of Medicine, Northwest Minzu University, Lanzhou, 730050, China.
Abstract:
Diabetic macular edema (DME) is one of the leading causes of blindness in diabetic retinopathy. As a domestically developed fusion protein drug in China, the anti-vascular endothelial growth factor (VEGF) agent Conbercept has demonstrated significant efficacy in the treatment of DME in recent years. This systematic review explores the mechanism of action and latest research advancements of Conbercept in DME treatment, integrating clinical trial data and comparisons with other anti-VEGF therapies. It further discusses existing limitations in current research and proposes future research directions.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview

